Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OFFLOAD-SHOCK: Optimal Timing of Renal Replacement Therapy in Hypervolemic Cardiogenic Shock
NCT07756801Phase 4Not yet recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Dec 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cardiogenic shock and hypervolemia (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoints: All-cause mortality at 90 days, Increased serum lactate at 24 hours and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
cardiogenic shockhypervolemia
Beyond the preview
Go deeper on NCT07756801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756801.